Swedish Orphan Biovitrum AB (publ) (SWOBY)
OTCMKTS
· Delayed Price · Currency is USD
14.00
0.00 (0.00%)
At close: Apr 17, 2025
SWOBY Revenue
In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B SEK with 17.65% growth. Swedish Orphan Biovitrum AB had revenue of 7.44B in the quarter ending December 31, 2024, with 8.65% growth.
Revenue
26.03B SEK
Revenue Growth
+17.65%
P/S Ratio
4.21
Revenue / Employee
14.41M SEK
Employees
1,806
Market Cap
9.90B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 20.65M |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |